Posters/Publications

poster

Denifanstat showed anti-fibrotic effect both on conventional and digital pathology in a metabolic dysfunction-associated steatohepatitis (MASH) Phase 2b trial (FASCINATE-2)

MASH TAG

Date - 01/2025
oral

AI-Based Digital Pathology Shows that Denifanstat Improves Multiple Parameters of Fibrosis and Reduces Progression to Cirrhosis in MASH patients with F2/F3

AASLD The Liver Meeting

Date - 11/2024
poster

Denifanstat significantly improves liver fibrosis in difficult-to-treat MASH patients – Results from conventional and AI-based pathology from the phase 2b FASCINATE-2, a 52-week randomized, double-blind, placebo-controlled trial

AASLD The Liver Meeting

Date - 11/2024
poster

Fatty acid synthase (FASN) inhibitor reduces atherosclerosis development in diet-induced dyslipidaemia LDL receptor knockout mice with MASH

AASLD The Liver Meeting

Date - 11/2024
paper

Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial

The Lancet Gastroenterology & Hepatology

Date - 10/2024
oral

Demonstrating denifanstat’s differentiated approach in MASH with mechanistic and clinical data showing direct anti-fibrotic activity

8th Annual MASH Drug Development Summit

Date - 09/2024
poster

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH

EASL International Liver Congress

Date - 06/2024
poster

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of MASH and cardiovascular health in LDL receptor knockout MASH mice

EASL International Liver Congress

Date - 06/2024
oral

Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week global, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis

EASL International Liver Congress

Date - 06/2024
oral

Evaluation of FASN inhibitor & GLP-1 Combination in Preclinical Mouse Model

7th Obesity and NASH Drug Development Summit

Date - 11/2023
Site map
Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2025 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

Scroll to Top